Myloop (Ethinylestradiol, Etonogestrel)

Ethinylestradiol, the active ingredient in Myloop, is a combined estrogen‑progestogen contraceptive presented as a vaginal ring for vaginal use. It prevents pregnancy by delivering continuous hormone levels to women of reproductive age, and the ring also contains etonogestrel, a progestogen that works synergistically with ethinylestradiol to maintain contraceptive efficacy.

GNH USA supplies Myloop as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across markets. The company provides reliable logistics and documentation for cross‑border procurement.

Myloop, a combined estrogen‑progestogen contraceptive, is indicated for hormonal contraception.

- Contraception (prevention of pregnancy): provides reliable reversible birth control for women of reproductive age. - Family planning: enables controlled spacing of pregnancies to support reproductive health goals. - Menstrual cycle regulation: may reduce menstrual bleeding and dysmenorrhea while maintaining contraceptive protection.

Myloop may be associated with a range of adverse reactions, which are generally categorized by frequency and severity.

Common Side Effects: - Vaginal irritation or discharge: mild irritation, spotting or increased discharge at the insertion site. - Headache: transient tension‑type or migraine‑like headaches. - Nausea or abdominal discomfort: mild gastrointestinal upset. - Breast tenderness: temporary swelling or sensitivity of the breasts.

Serious or Rare Side Effects: - Thromboembolic events: deep‑vein thrombosis or pulmonary embolism, requiring immediate medical attention. - Hepatic disorders: liver enzyme elevation or rare hepatic adenoma. - Severe allergic reaction: anaphylaxis, angioedema, or Stevens‑Johnson syndrome.

Before prescribing Myloop, healthcare professionals should consider several precautionary measures to ensure patient safety. - Pregnancy contraindication: do not use in women who are or may become pregnant. - Smoking restriction: avoid use in women who smoke more than 15 cigarettes per day. - History of thromboembolism: contraindicated in patients with prior venous or arterial clotting events. - Liver disease: use with caution in patients with active liver disease or tumors. - Breast cancer: contraindicated in current or past estrogen‑dependent breast cancer. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Myloop can interact with other medicines, altering its contraceptive effectiveness or increasing adverse effect risk.

Major Interactions (Avoid): - Enzyme‑inducing anticonvulsants (e.g., carbamazepine, phenytoin, phenobarbital): markedly reduce hormone levels, risking contraceptive failure. - Rifampin and other strong CYP3A4 inducers: decrease ethinylestradiol and etonogestrel concentrations. - St. John’s wort (hypericum perforatum): herbal inducer that may compromise contraceptive efficacy.

Moderate Interactions (Monitor Closely): - Antifungal agents such as ketoconazole or itraconazole: may increase hormone exposure, requiring monitoring for side effects. - Selective serotonin reuptake inhibitors (SSRIs): can modestly increase risk of mood changes or bleeding. - Antihypertensive drugs (e.g., ACE inhibitors): may require blood pressure monitoring due to possible fluid retention.